Startup launches with $245 million for twice yearly asthma treatment

A new biotech has raised $245 million to test a new asthma medication that could compete with one sold by Amgen and AstraZeneca.

The startup, Aiolos Therapeutics, was founded by former Genentech colleagues Khurem Farooq and Tony Adamis after they stumbled upon a drug being developed by Chinese pharma company Jiangsu Hengrui Pharmaceuticals Co., Ltd. The two men believed there was an unmet need in asthma, and in Jiangsu’s drug, a potential game-changer.

The experimental medication, AIO-001, is similar to Amgen and AstraZeneca’s new product Tezspire: Both work by inhibiting the thymic stromal lymphopoietin, or TSLP, which is over-expressed by people with asthma and causes airway inflammation. (Another startup, Upstream Bio, announced Tuesday that its subcutaneous TSLP inhibitor is also showing promise in a Phase 1 trial.)

Get unlimited access to award-winning journalism and exclusive events.

New ESC Guidelines for the management of cardiovascular disease in patients with diabetes released

Patients with type 2 diabetes are more than twice as likely to develop cardiovascular disease (CVD) than their healthy peers.

August 25, 2023

Oxurion to file for bankruptcy following trial failure

Share this article Oxurion cited low cash reserves as the precipitating factor for filing for bankruptcy. Image Credit: PENpics Studio / Shutterstock. Oxurion has started

November 20, 2023

WHO and Government of France host high-level meeting to combat meningitis

Global leaders highlight the need to defeat meningitis – a leading cause of disability – at a high-level meeting co-hosted by the World Health Organization

April 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.